Factors that influence prognosis in SM-AHN

Compared with indolent systemic mastocytosis (ISM), SM with associated hematologic, specifically myeloid, neoplasms (AHN/AMN) has a very poor prognosis. In this episode, Dr. Andrew Kuykendall discusses the factors associated with a worse prognosis in SM-AHN/AMN and how outcomes may be improving in the era of KIT inhibitors.

Spend Your Monday Mornings with Us!

Monday Morning Joe with Andrew Kuykendall, MD

October 2: Overview of the heterogeneous presentations of SM-AHN

October 9: Pathogenesis and driver mutations in SM-AHN:

October 16: Challenges in diagnosis of SM-AHN

October 23: Factors that influence prognosis in SM-AHN - You are here now!

October 30: Treatment decision-making for SM-AHN

ExchangeCME.com is an online community of more than 49,000 active healthcare professionals who have access to a variety of enduring educational activities and other disease state–focused resources. The Website’s core mission is to support patient-centered care via education that is tailored to the needs of various clinician audiences.

By consolidating evidence-based resources and hosting only accredited educational programs without any promotional content or advertising, ExchangeCME.com serves as an independent, trusted, and balanced source of free CME/CE for physicians, nurses, pharmacists, and other healthcare providers.

Follow us on social!